Catamaran Bio Announces Lead CAR-NK Cell Therapy Programs and Upcoming Data Presentation at ASH 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catamaran Bio, Inc., a biotechnology company developing off-the-shelf CAR-NK cell therapies to treat cancer, today announced that it has designated CAT-179, a ...
SEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BrainChild Bio, Inc., a clinical-stage biotechnology company developing CAR T-cell therapies to treat tumors in the central nervous system (CNS), today ...
Cabaletta Bio is developing targeted cellular therapies for autoimmune diseases, including systemic lupus erythematous and myositis. Their lead program, CABA-201, is a CD19 chimeric antigen receptor ...
MINNEAPOLIS and CAMBRIDGE, Mass., June 24, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Catamaran Bio today announced an expansion of their collaboration for the development of cell ...
Landmark Bio will serve as strategic point-of-care manufacturing partner for Galapagos' CAR-T product candidates in the Boston area Under the terms of the agreement, Landmark Bio will perform GMP ...
WORCESTER, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies ...
Regeneron has given up on a CAR-T candidate acquired from 2seventy bio last year, before it entered the second part of a phase 1/2 lymphoma study. The dual-targeting CAR-T, dubbed bbT369, was being ...
SHANGHAI, NANJING, China and PLEASANTON, Calif., Sept. 18, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and ...
Immpact Bio USA Inc. has obtained IND clearance from the FDA for IMPT-514, a CD19/CD20 bispecific chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results